Updated analysis of DESTINY-Gastric02: A phase II singlearm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/ metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen Meeting Abstract


Authors: Ku, G. Y.; Di Bartolomeo, M.; Smyth, E.; Chau, I.; Park, H.; Siena, S.; Lonardi, S.; Wainberg, Z. A.; Ajani, J. A.; Chao, J.; Barlaskar, F.; Kawaguchi, Y.; Qin, A.; Singh, J.; Meinhardt, G.; Van Cutsem, E.
Abstract Title: Updated analysis of DESTINY-Gastric02: A phase II singlearm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/ metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
Meeting Title: ESMO Congress 2022
Journal Title: Annals of Oncology
Volume: 33
Issue: Suppl. 7
Meeting Dates: 2022 Sep 9-13
Meeting Location: Paris, France
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2022-09-01
Start Page: S1100
Language: English
ACCESSION: WOS:000866211601467
PROVIDER: wos
DOI: 10.1016/j.annonc.2022.07.1323
Notes: Meeting Abstract: 1205MO -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Geoffrey Yuyat Ku
    236 Ku